Prepare for the definitive meeting dedicated to refining analytics to ensure the swift progression of highly efficacious products through IND and clinical trials, ultimately securing regulatory approval at the 6th Cell Therapy Analytical Development Summit. From December 3-5, 2024, visionaries and leaders from across the cell therapy space will convene to advance analytical testing and confidently characterize cell potency, safety, and viability.
Effectively demonstrating the superior safety and efficacy of your cell therapy product is crucial to standing out in a competitive market and attracting investment. Now, more than ever, it’s essential to prioritize integrating cutting-edge technologies and robust analytical methods to showcase your product’s unique qualities.
Featuring industry titans such as BMS, Kite, Regeneron, Takeda, Arsenal Bio, KSQ, Century Therapeutics, the Alliance for Regenerative Medicine, and many more, this summit will provide insights into the latest breakthroughs and strategies to overcome the most pressing challenges in the field. Topics will include achieving assay standardization, tech transfer, regulatory compliance, and the adoption of advanced analytical techniques like ddPCR, single-cell analysis, high-content imaging, and omics technologies.
Don’t miss your chance to be part of this critical discussion on advancing quality control and analytical methods.
For more information, visit the 6th Cell Therapy Analytical Development Summit website here: https://ter.li/qinrcx
Presented By:
Jenna Scott
Program Director
Hanson Wade